Home > Healthcare & Medical Devices > Endometrial Ablation Devices Market
Endometrial Ablation Devices Market size is projected to amass considerable returns between 2023-2032, on account of the myriad benefits of uterine ablation procedures, such as reduced risks of uterine infection and faster recovery. The demand for these devices is also surging amongst the female population owing to the irregular blood flow in between the menstrual cycles. As per Endometriosis UK statistics, approximately 10% of the global female population suffer from the condition.
In addition, the rapid advancements in minimally invasive surgical techniques and the rising burden of gynecological disorders including cervical cancer will also impel the adoption of endometrial ablation procedures in the upcoming years.
Rising burden of hormone disorders like polycystic ovary syndrome (PCOS) among women is one of the major factors amplifying the endometrial ablation devices market over 2023-2032. According to the CDC estimates, PCOS affects nearly 6% to 12% of the American women of reproductive age, and is one of the leading causes of infertility, which is likely to contribute to the overall industry forecast.
Moreover, the growing emphasis on boosting awareness of gynecological cancer, along with the growing incidence of adenomyosis in women, particularly after 50 years of age, will also assert a positive influence on endometrial ablation surgery progression globally. Despite these favorable growth environments, the risks and complications associated with uterine ablation surgery such as uterine perforation, shortness of breath, and high fever may create a hindrance to the market dynamics to a certain extent.
Nonetheless, constant technological innovations in endometrial ablation devices to support quick patient response and recovery would potentially support the endometrial ablation devices market dynamics. This would enable companies to build on the innovation and introduce novel products in the marketplace. For instance, in 2023, Hologic Inc. announced approval of NovaSure V5 global endometrial ablation device in European and Canadian markets. The device incorporates improved features and an updated cervical seal, equipped with EndoForm technology designed to accommodate a range of cervical canals and increase the sealing surface.
Cryoablation technology segment across the overall endometrial ablation devices industry is anticipated to hold a considerable share by 2032 end. The segmental revenue can be credited to the high safety and less-invasive nature of the cryoablation procedure as compared to surgery. Fewer side effects, cost-effectiveness, and less damage to surrounding tissues, among other advantages of this technology will further push segmental expansion over the coming years.
Based on end-user, the endometrial ablation devices market from ambulatory surgical centers segment would accrue profitable gains over the next ten years. Potential benefits offered by ASCs including lower cost of care, reduced time, increase safety, superior convenience and affordability, and predictable scheduling would accelerate the market progression.
Geographically, Europe endometrial ablation devices industry will register appreciable value by 2032, considering the robust healthcare system in countries including Germany, especially with regards to hospital beds, trained staff, and infrastructure. Additionally, the escalating healthcare expenditure and the high prevalence of cervical cancer in countries like the UK and France, are expected to fuel the regional market outlook in the years ahead.
The competitive landscape of the endometrial ablation devices market consists of companies such as AngioDynamics, Medtronic, Richard Wolf GmbH, Karl Storz GmbH & Co. KG, Hologic, Inc., The Cooper Companies Inc., Smith & Nephew, Minerva Surgical, Olympus Corporation, and Boston Scientific Corporation, among others.